Cost-effectiveness of 3 statin sample policies in post-myocardial infarction patients

Rola Kaakeh, David W. Hutton, Kylee Funk, Justin Gatwood, Bernadette Chan, Maha Salah-Ud-Din

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: To compare several drug-sampling policies with respect to their potential cost-effectiveness. Study Design: A cost-effectiveness analysis, Markov model, from both health system and payer cost perspectives. Methods: A Markov model with a 10-year time horizon was used to evaluate the cost-effectiveness of the provision of statin samples for statin-naïve, post-myocardial infarction (MI) patients starting at age 65 years from both the health system and payer cost perspectives. Three scenarios were evaluated: no samples, generic samples, and brand samples. Probability inputs were determined using existing data from previous trials and analyses. Secondary sources were used to determine costs and health utilities. Sensitivity analysis was conducted on variables to test robustness and uncertainty in the model. TreeAge Inc software was used, and both utilities and costs were discounted at 3%. Results: Generic sampling was the dominant strategy, having the highest quality-adjusted life-years (QALYs) and lowest costs. The model calculated that a patient who starts taking generic statin samples will have 5.86 discounted QALYs and costs of $47,805, whereas a patient who starts taking brand statin samples will have 5.77 discounted QALYs and costs of $52,868. Sensitivity analysis revealed that the annual probability of a recurrent MI if the patient stops adhering to statins and the probability that the patient will continue adhering to statins while on generic statins affected whether generic sampling was preferred. Conclusion: Use of generic samples should be extended and further evaluated to improve health outcomes and reduce costs.

Original languageEnglish (US)
JournalAmerican Journal of Pharmacy Benefits
Volume5
Issue number2
StatePublished - Mar 1 2013
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cost-Benefit Analysis
Myocardial Infarction
Costs and Cost Analysis
Quality-Adjusted Life Years
Health
Costs
Cost-effectiveness
Myocardial infarction
Health Care Costs
Uncertainty
Software
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Business and International Management
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Decision Sciences (miscellaneous)

Cite this

Cost-effectiveness of 3 statin sample policies in post-myocardial infarction patients. / Kaakeh, Rola; Hutton, David W.; Funk, Kylee; Gatwood, Justin; Chan, Bernadette; Salah-Ud-Din, Maha.

In: American Journal of Pharmacy Benefits, Vol. 5, No. 2, 01.03.2013.

Research output: Contribution to journalArticle

Kaakeh, Rola ; Hutton, David W. ; Funk, Kylee ; Gatwood, Justin ; Chan, Bernadette ; Salah-Ud-Din, Maha. / Cost-effectiveness of 3 statin sample policies in post-myocardial infarction patients. In: American Journal of Pharmacy Benefits. 2013 ; Vol. 5, No. 2.
@article{cb697704b59647a8bcad118fbf4eba17,
title = "Cost-effectiveness of 3 statin sample policies in post-myocardial infarction patients",
abstract = "Objectives: To compare several drug-sampling policies with respect to their potential cost-effectiveness. Study Design: A cost-effectiveness analysis, Markov model, from both health system and payer cost perspectives. Methods: A Markov model with a 10-year time horizon was used to evaluate the cost-effectiveness of the provision of statin samples for statin-na{\"i}ve, post-myocardial infarction (MI) patients starting at age 65 years from both the health system and payer cost perspectives. Three scenarios were evaluated: no samples, generic samples, and brand samples. Probability inputs were determined using existing data from previous trials and analyses. Secondary sources were used to determine costs and health utilities. Sensitivity analysis was conducted on variables to test robustness and uncertainty in the model. TreeAge Inc software was used, and both utilities and costs were discounted at 3{\%}. Results: Generic sampling was the dominant strategy, having the highest quality-adjusted life-years (QALYs) and lowest costs. The model calculated that a patient who starts taking generic statin samples will have 5.86 discounted QALYs and costs of $47,805, whereas a patient who starts taking brand statin samples will have 5.77 discounted QALYs and costs of $52,868. Sensitivity analysis revealed that the annual probability of a recurrent MI if the patient stops adhering to statins and the probability that the patient will continue adhering to statins while on generic statins affected whether generic sampling was preferred. Conclusion: Use of generic samples should be extended and further evaluated to improve health outcomes and reduce costs.",
author = "Rola Kaakeh and Hutton, {David W.} and Kylee Funk and Justin Gatwood and Bernadette Chan and Maha Salah-Ud-Din",
year = "2013",
month = "3",
day = "1",
language = "English (US)",
volume = "5",
journal = "American Journal of Pharmacy Benefits",
issn = "1945-4481",
publisher = "Managed Care and Healthcare Communications",
number = "2",

}

TY - JOUR

T1 - Cost-effectiveness of 3 statin sample policies in post-myocardial infarction patients

AU - Kaakeh, Rola

AU - Hutton, David W.

AU - Funk, Kylee

AU - Gatwood, Justin

AU - Chan, Bernadette

AU - Salah-Ud-Din, Maha

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Objectives: To compare several drug-sampling policies with respect to their potential cost-effectiveness. Study Design: A cost-effectiveness analysis, Markov model, from both health system and payer cost perspectives. Methods: A Markov model with a 10-year time horizon was used to evaluate the cost-effectiveness of the provision of statin samples for statin-naïve, post-myocardial infarction (MI) patients starting at age 65 years from both the health system and payer cost perspectives. Three scenarios were evaluated: no samples, generic samples, and brand samples. Probability inputs were determined using existing data from previous trials and analyses. Secondary sources were used to determine costs and health utilities. Sensitivity analysis was conducted on variables to test robustness and uncertainty in the model. TreeAge Inc software was used, and both utilities and costs were discounted at 3%. Results: Generic sampling was the dominant strategy, having the highest quality-adjusted life-years (QALYs) and lowest costs. The model calculated that a patient who starts taking generic statin samples will have 5.86 discounted QALYs and costs of $47,805, whereas a patient who starts taking brand statin samples will have 5.77 discounted QALYs and costs of $52,868. Sensitivity analysis revealed that the annual probability of a recurrent MI if the patient stops adhering to statins and the probability that the patient will continue adhering to statins while on generic statins affected whether generic sampling was preferred. Conclusion: Use of generic samples should be extended and further evaluated to improve health outcomes and reduce costs.

AB - Objectives: To compare several drug-sampling policies with respect to their potential cost-effectiveness. Study Design: A cost-effectiveness analysis, Markov model, from both health system and payer cost perspectives. Methods: A Markov model with a 10-year time horizon was used to evaluate the cost-effectiveness of the provision of statin samples for statin-naïve, post-myocardial infarction (MI) patients starting at age 65 years from both the health system and payer cost perspectives. Three scenarios were evaluated: no samples, generic samples, and brand samples. Probability inputs were determined using existing data from previous trials and analyses. Secondary sources were used to determine costs and health utilities. Sensitivity analysis was conducted on variables to test robustness and uncertainty in the model. TreeAge Inc software was used, and both utilities and costs were discounted at 3%. Results: Generic sampling was the dominant strategy, having the highest quality-adjusted life-years (QALYs) and lowest costs. The model calculated that a patient who starts taking generic statin samples will have 5.86 discounted QALYs and costs of $47,805, whereas a patient who starts taking brand statin samples will have 5.77 discounted QALYs and costs of $52,868. Sensitivity analysis revealed that the annual probability of a recurrent MI if the patient stops adhering to statins and the probability that the patient will continue adhering to statins while on generic statins affected whether generic sampling was preferred. Conclusion: Use of generic samples should be extended and further evaluated to improve health outcomes and reduce costs.

UR - http://www.scopus.com/inward/record.url?scp=84876564436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876564436&partnerID=8YFLogxK

M3 - Article

VL - 5

JO - American Journal of Pharmacy Benefits

JF - American Journal of Pharmacy Benefits

SN - 1945-4481

IS - 2

ER -